Literature DB >> 23752731

Biological markers: Tailoring treatment and trials to prognosis.

David J Kerr1, Yuankai Shi.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23752731     DOI： 10.1038/nrclinonc.2013.97

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Defective mismatch repair in colon cancer: a prognostic or predictive biomarker?

Authors:  David J Kerr; Rachel Midgley
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

2.  Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.

Authors:  Richard G Gray; Philip Quirke; Kelly Handley; Margarita Lopatin; Laura Magill; Frederick L Baehner; Claire Beaumont; Kim M Clark-Langone; Carl N Yoshizawa; Mark Lee; Drew Watson; Steven Shak; David J Kerr
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

3.  Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer.

Authors:  Ramon Salazar; Paul Roepman; Gabriel Capella; Victor Moreno; Iris Simon; Christa Dreezen; Adriana Lopez-Doriga; Cristina Santos; Corrie Marijnen; Johan Westerga; Sjoerd Bruin; David Kerr; Peter Kuppen; Cornelis van de Velde; Hans Morreau; Loes Van Velthuysen; Annuska M Glas; Laura J Van't Veer; Rob Tollenaar
Journal:  J Clin Oncol       Date:  2010-11-22       Impact factor: 44.544

4.  ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.

Authors:  H J Schmoll; E Van Cutsem; A Stein; V Valentini; B Glimelius; K Haustermans; B Nordlinger; C J van de Velde; J Balmana; J Regula; I D Nagtegaal; R G Beets-Tan; D Arnold; F Ciardiello; P Hoff; D Kerr; C H Köhne; R Labianca; T Price; W Scheithauer; A Sobrero; J Tabernero; D Aderka; S Barroso; G Bodoky; J Y Douillard; H El Ghazaly; J Gallardo; A Garin; R Glynne-Jones; K Jordan; A Meshcheryakov; D Papamichail; P Pfeiffer; I Souglakos; S Turhal; A Cervantes
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

5.  Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

Authors:  Gordon Hutchins; Katie Southward; Kelly Handley; Laura Magill; Claire Beaumont; Jens Stahlschmidt; Susan Richman; Philip Chambers; Matthew Seymour; David Kerr; Richard Gray; Philip Quirke
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

6.  Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

Authors:  Eric Van Cutsem; Roberto Labianca; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Claire Topham; Josep Tabernero; Thierry André; Alberto F Sobrero; Enrico Mini; Richard Greil; Francesco Di Costanzo; Laurence Collette; Laura Cisar; Xiaoxi Zhang; David Khayat; Carsten Bokemeyer; Arnaud D Roth; David Cunningham
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

7.  The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial.

Authors:  A Huijbers; R A E M Tollenaar; G W v Pelt; E C M Zeestraten; S Dutton; C C McConkey; E Domingo; V T H B M Smit; R Midgley; B F Warren; E C Johnstone; D J Kerr; W E Mesker
Journal:  Ann Oncol       Date:  2012-08-02       Impact factor: 32.976

Review 8.  Predictive biomarkers: a paradigm shift towards personalized cancer medicine.

Authors:  Nicholas B La Thangue; David J Kerr
Journal:  Nat Rev Clin Oncol       Date:  2011-08-23       Impact factor: 66.675

9.  Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.

Authors:  Enric Domingo; Rajarajan Ramamoorthy; Dahmane Oukrif; Daniel Rosmarin; Michal Presz; Haitao Wang; Hannah Pulker; Helen Lockstone; Tarjei Hveem; Treena Cranston; Havard Danielsen; Marco Novelli; Brian Davidson; Zheng-Zhou Xu; Peter Molloy; Elaine Johnstone; Christopher Holmes; Rachel Midgley; David Kerr; Oliver Sieber; Ian Tomlinson
Journal:  J Pathol       Date:  2013-02       Impact factor: 7.996

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1976-12       Impact factor: 7.640
  10 in total
  1 in total

1.  Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs.

Authors:  Narayan Shivapurkar; Louis M Weiner; John L Marshall; Subha Madhavan; Anne Deslattes Mays; Hartmut Juhl; Anton Wellstein
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.